← Back to Discover

TYBOURNE CAPITAL MANAGEMENT (HK) LTD

Period ended Sep 30, 2025 · Latest filing Nov 6, 2025

These quarterly holdings are delayed and may not include all assets or short positions. Values are from the reporting date, not current prices or purchase costs. The same security may appear in multiple rows.

Source: SEC

Reported portfolio value

Quarter-end reported holdings; not current value or investment performance.

View reported values
  • Sep 30, 2025: $30,933,557

More quarters will appear as history becomes available.

Top holdings

Top 10 at Sep 30, 2025. Matching entries are combined; security classes and options remain separate. Shares exclude principal amounts; option shares reflect the reported underlying amount.

View top holdings values
  1. TAYSHA GENE THERAPIES INC (TSHA US) · COM SHS · 877619106 · shares: $12,099,000
  2. FORTE BIOSCIENCES INC (FBRX US) · COM NEW · 34962G208 · shares: $11,799,705
  3. ALUMIS INC (ALMS US) · COM · 022307102 · shares: $5,583,008
  4. ZENTALIS PHARMACEUTICALS INC (ZNTL US) · COM · 98943L107 · shares: $1,451,844

Reported holdings

4 reported entries
IssuerClassCUSIPTypeShares / principalReported value (USD)
TAYSHA GENE THERAPIES INC (TSHA US)COM SHS877619106 — 3,700,000 shares $12,099,000
FORTE BIOSCIENCES INC (FBRX US)COM NEW34962G208 — 786,647 shares $11,799,705
ALUMIS INC (ALMS US)COM022307102 — 1,399,250 shares $5,583,008
ZENTALIS PHARMACEUTICALS INC (ZNTL US)COM98943L107 — 961,486 shares $1,451,844